Created by Portia K.C.
It
It has been a promising year for the
pharmaceutical industry in 2013. The total
drugs spent increased sharply to a 3.2%...
Created by Portia K.C.
Created by Portia K.C.
#1
Abilify
Otsuka/BMS
#2
Nexium
AstraZeneca
#3
Humira
AbbVie
#4
Crestor
AstraZeneca
#5
Cymbalta
Eli Lilly
# 6
Advair Disku...
Created by Portia K.C.
0 5 10 15 20 25 30
Nervous System Disorders
Antibacterials
Dermatologicals
ADHD
Anti-Ulcerants
Mutl...
Rank Company 2013 Total Promo Spending (Millions)*
1 Pfizer $1,858.85
2 Merck & Co. $1,489.41
3 Forest Laboratries $1,139....
Created by Portia K.C.
Drug Developed
IND Application
Animals Tested
CLINICAL
Drug Sponsor’s Clinical Studies/Trials
p
h
a
s
e
1
20-80 healthy vo...
Created by Portia K.C.
Upcoming SlideShare
Loading in …5
×

Pharma report 2014 by portiak

1,217 views

Published on

Key Factors Point to the New Generation of Medicine

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,217
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
7
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Pharma report 2014 by portiak

  1. 1. Created by Portia K.C.
  2. 2. It It has been a promising year for the pharmaceutical industry in 2013. The total drugs spent increased sharply to a 3.2%; however, we must be well-prepared for the new generation of medicine and changes in the upcoming 2015. Now, it is time to look back and analyze the key factors of 2013 and the 1st quarter of 2014. Created by Portia K.C.
  3. 3. Created by Portia K.C.
  4. 4. Created by Portia K.C.
  5. 5. #1 Abilify Otsuka/BMS #2 Nexium AstraZeneca #3 Humira AbbVie #4 Crestor AstraZeneca #5 Cymbalta Eli Lilly # 6 Advair Diskus GlaxoSmithKline #7 Enbrel Amgen #8 Remicade Johnson& Johnson #9 Copaxone Teva #10 Neulasta Amgen $6.6 $6.2 $5.6 $5.4 $5.3 $5.2 $4.7 $4.1 $3.7 $3.6 2013 Total (Billions) Created by Portia K.C.
  6. 6. Created by Portia K.C. 0 5 10 15 20 25 30 Nervous System Disorders Antibacterials Dermatologicals ADHD Anti-Ulcerants Mutliple Sclerosis HIV Antivirals Antihypertensives Lipid Regulartors Autoimmune Pain Respiratory Metal Health Antidiabetes Oncologics 8.1 8.6 8.9 9.9 10 10.6 12.5 12.5 13.6 17.9 18.7 20.4 23.7 24.3 27.9 Top 15 Therapeutic Classes by US Sales 2013 2013 Total (Billions)
  7. 7. Rank Company 2013 Total Promo Spending (Millions)* 1 Pfizer $1,858.85 2 Merck & Co. $1,489.41 3 Forest Laboratries $1,139.22 4 AstraZeneca $1,137.77 5 Eli Lilly $1,063.02 6 Boehringer Ingelheim $833.41 7 Novartis $810.38 8 GlaxoSmithKline $802.99 9 BMS $787.86 10 Johnson & Johnson $755.92 11 Novo Nordisk $572.06 12 Daiichi Sankyo $502.52 13 Sanofi $486.99 14 Takeda $479.98 15 Amgen $398.08 16 Abbvie $369.24 17 Allergan $360.60 18 Otsuka Pharmaceutical Group $353.22 19 Teva $300.59 20 Sunovion $281.65 2013 US Total Promotional Spending * Total promotional spend figure includes total promo DTC, eDetailing, professional detailing, professional meetings, journal ads/publication ads, but it does not include amount spent on samples, clinical trials or direct mail. Created by Portia K.C.
  8. 8. Created by Portia K.C.
  9. 9. Drug Developed IND Application Animals Tested CLINICAL Drug Sponsor’s Clinical Studies/Trials p h a s e 1 20-80 healthy volunteers P h a s e 2 100’s patients P h a s e 3 1000’s patients NDA REVIEW FDA’s New Drug Application (NDA) Review POST-MARKETING FDA’s Post-Approval Risk Assessment Systems Phase 4 Once FDA approves a drug, the post-marketing monitoring begins. The sponsor (typically the manufacturer) is required to submit periodic safety updates to FDA Review Meeting NDA Application Application Reviewed Drug Labelling Facility Inspection Drug Approval Created by Portia K.C.
  10. 10. Created by Portia K.C.

×